These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23198151)

  • 21. Regulatory mechanisms of osteoblast and osteoclast differentiation.
    Katagiri T; Takahashi N
    Oral Dis; 2002 May; 8(3):147-59. PubMed ID: 12108759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HTLV-1 infected T cells cause bone loss via small extracellular vesicles.
    Pokhrel NK; Panfil A; Habib H; Seeniraj S; Joseph A; Rauch D; Cox L; Sprung R; Gilmore PE; Zhang Q; Townsend RR; Yu L; Yilmaz AS; Aurora R; Park W; Ratner L; Weilbaecher KN; Veis DJ
    bioRxiv; 2024 Mar; ():. PubMed ID: 38496506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification.
    Tseng W; Graham LS; Geng Y; Reddy A; Lu J; Effros RB; Demer L; Tintut Y
    J Biol Chem; 2010 Sep; 285(39):29925-31. PubMed ID: 20663885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells.
    Granchi D; Amato I; Battistelli L; Avnet S; Capaccioli S; Papucci L; Donnini M; Pellacani A; Brandi ML; Giunti A; Baldini N
    Int J Cancer; 2004 Oct; 111(6):829-38. PubMed ID: 15300794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Action of RANKL and OPG for osteoclastogenesis.
    Kobayashi Y; Udagawa N; Takahashi N
    Crit Rev Eukaryot Gene Expr; 2009; 19(1):61-72. PubMed ID: 19191757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
    Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
    Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
    Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone.
    Faucheux C; Horton MA; Price JS
    J Bone Miner Res; 2002 Mar; 17(3):455-64. PubMed ID: 11874237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
    Kostenuik PJ; Shalhoub V
    Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue.
    Ogasawara T; Yoshimine Y; Kiyoshima T; Kobayashi I; Matsuo K; Akamine A; Sakai H
    J Periodontal Res; 2004 Feb; 39(1):42-9. PubMed ID: 14687227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
    Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
    Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.